PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First-Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study

Abstract

This multicenter study aimed to investigate the efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy (ICI-Chemo group) versus chemotherapy alone (Chemo group) for patients with cancer of unknown primary (CUP) in the first-line setting. We included patients with unfavorable CUP across four medical centers in China. Between January 2014 and December 2023, 117 patients were enrolled: 46 patients in the ICI-Chemo group and 71 patients in the Chemo group. After a median follow-up of 28.1 months, the ICI-Chemo group exhibited a significant improvement over the Chemo group in median PFS (9.10 months vs. 6.37 months; hazard ratio [HR] 0.46; 95% CI: 0.30–0.71; p < 0.001) and OS (35.67 months vs. 10.2 months; HR 0.37; 95% CI: 0.22–0.64; p < 0.001). Similarly, among patients who received TP (taxane plus platinum)-based chemotherapies, OS and PFS benefits were observed in the ICI-Chemo group. The objective response rate was higher in the ICI-Chemo group than in the Chemo group (54.35% vs. 22.53%, p < 0.001). Grade 3 or higher drug-related adverse events occurred in 11 patients (23.91%) in the ICI-Chemo group and 28 patients (39.44%) in the Chemo group. Thus, PD-1/PD-L1 inhibitors plus chemotherapy could be the preferred first-line treatment for patients with unfavorable CUP, providing improved efficacy and manageable toxicity.

Keywords

cancer of unknown primary / chemotherapy / first-line therapy / overall survival / PD-1/PD-L1 inhibitors

References

[1] A. Krämer, T. Bochtler, C. Pauli, et al., “Cancer of Unknown Primary: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 34, no. 3 (2023): 228–246

[2] N. Pavlidis and K. Fizazi, “Carcinoma of Unknown Primary (CUP)” Critical Reviews in Oncology/Hematology 69, no. 3 (2009): 271–278. .

[3] D. Petrakis, G. Pentheroudakis, E. Voulgaris, and N. Pavlidis, “Prognostication in Cancer of Unknown Primary (CUP): Development of a Prognostic Algorithm in 311 Cases and Review of the Literature,” Cancer Treatment Reviews 39, no. 7 (2013): 701–708.

[4] N. Pavlidis, H. Khaled, and R. Gaafar, “A Mini Review on Cancer of Unknown Primary Site: A Clinical Puzzle for the Oncologists,” Journal of Advanced Research 6, no. 3 (2015): 375–382.

[5] F. A. Greco and N. Pavlidis, “Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors,” Seminars in Oncology 36, no. 1 (2009): 65–74.

[6] J. Lee, S. Hahn, D. W. Kim, et al., “Evaluation of Survival Benefits by Platinums and Taxanes for an Unfavourable Subset of Carcinoma of Unknown Primary: A Systematic Review and Meta-Analysis,” British Journal of Cancer 108, no. 1 (2013): 39–48.

[7] E. Briasoulis, H. Kalofonos, D. Bafaloukos, et al., “Carboplatin Plus Paclitaxel in Unknown Primary Carcinoma: A Phase II Hellenic Cooperative Oncology Group Study,” Journal of Clinical Oncology 18, no. 17 (2000): 3101–3107.

[8] F. A. Greco, J. B. Erland, L. H. Morrissey, et al., “Carcinoma of Unknown Primary Site: Phase II Trials With Docetaxel Plus Cisplatin or Carboplatin,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 11, no. 2 (2000): 211–215.

[9] H. Hayashi, T. Kurata, Y. Takiguchi, et al., “Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients with Cancer of Unknown Primary Site,” Journal of Clinical Oncology 37, no. 7 (2019): 570–579.

[10] J. D. Hainsworth, M. S. Rubin, D. R. Spigel, et al., “Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute,” Journal of Clinical Oncology 31, no. 2 (2013): 217–223.

[11] G. Huebner, H. Link, C. H. Kohne, et al., “Paclitaxel and Carboplatin vs Gemcitabine and Vinorelbine in Patients With Adeno-or Undifferentiated Carcinoma of Unknown Primary: A Randomised Prospective Phase II Trial,” British Journal of Cancer 100, no. 1 (2009): 44–49.

[12] K. Nishikawa, S. Hironaka, T. Inagaki, et al., “A Multicentre Retrospective Study Comparing Site-Specific Treatment With Empiric Treatment for Unfavourable Subset of Cancer of Unknown Primary Site,” Japanese Journal of Clinical Oncology 52, no. 12 (2022): 1416–1422.

[13] X. Liu, X. Zhang, S. Jiang, et al., “Site-Specific Therapy Guided by a 90-Gene Expression Assay Versus Empirical Chemotherapy in Patients With Cancer of Unknown Primary (Fudan CUP-001): A Randomised Controlled Trial,” Lancet Oncology 25, no. 8 (2024): 1092–1102.

[14] K. Haratani, H. Hayashi, T. Takahama, et al., “Clinical and Immune Profiling for Cancer of Unknown Primary Site,” Journal for Immunotherapy of Cancer 7, no. 1 (2019): 251.

[15] A. Singh, D. Singh, S. Boyes, and E. Henry, “Treatment of Metastatic Carcinoma of an Unknown Primary to the Heart With Checkpoint Inhibitor Therapy,” Oncology Research and Treatment 44, no. 4 (2021): 190–195.

[16] M. Zhang, M. Zhao, L. F. Jin, and W. Z. Shen, “Successful Treatment Using Immunotherapy in Combination With Chemotherapy for Metastatic Squamous Cell Carcinoma of Unknown Primary Origin With Bulky Abdominal Mass: A Case Report,” Medicine 100, no. 48 (2021): e28074.

[17] A. Komura, A. Taguchi, M. Ikemura, et al., “A Case of Refractory Pelvic Squamous Cell Carcinoma of Unknown Primary That Responded to Nivolumab,” Journal of Obstetrics and Gynaecology Research 49, no. 4 (2023): 1300–1304.

[18] W. Zhao, N. Zhao, M. Zhang, et al., “2-Year Survival Benefit From Immunotherapy for Squamous Cell Cancer With Cancer of Unknown Primary in Mediastinum: A Case Report,” Frontiers in Oncology 13 (2023): 1242460.

[19] R. Suzuki, K. Hamada, R. Ohkuma, et al., “Case Report: Combined Pembrolizumab, 5-Fluorouracil, and Cisplatin Therapy Were Remarkably Effective in p16-Positive Squamous Cell Carcinoma of Unknown Primary,” Frontiers in Oncology 13 (2023): 1231986.

[20] J. Sheng, H. Pan, and W. Han, “Immunochemotherapy Achieved a Complete Response for Metastatic Adenocarcinoma of Unknown Primary Based on Gene Expression Profiling: A Case Report and Review of the Literature,” Frontiers in Immunology 14 (2023): 1181444.

[21] J. Mei, H. Wang, H. Fan, J. Ding, and J. Xu, “Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary,” Frontiers in Immunology 13 (2022): 900119.

[22] T. Kamada, H. Ishiguro, S. Okada, et al., “Pembrolizumab Plus Platinum-Based Chemotherapy for Unfavorable Cancer of Unknown Primary Site: Case Report,” Annals of Medicine and Surgery (2012) 60 (2020): 31–35.

[23] M. Pouyiourou, B. N. Kraft, T. Wohlfromm, et al., “Nivolumab and Ipilimumab in Recurrent or Refractory Cancer of Unknown Primary: A Phase II Trial,” Nature Communications 14, no. 1 (2023): 6761.

[24] J. Tanizaki, K. Yonemori, K. Akiyoshi, et al., “Open-Label Phase II Study of the Efficacy of Nivolumab for Cancer of Unknown Primary,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 33, no. 2 (2022): 216–226.

[25] K. P. Raghav, B. Stephen, D. D. Karp, et al., “Efficacy of Pembrolizumab in Patients With Advanced Cancer of Unknown Primary (CUP): A Phase 2 Non-Randomized Clinical Trial,” Journal for Immunotherapy of Cancer 10, no. 5 (2022).

[26] H. Hayashi, Y. Takiguchi, H. Minami, et al., “Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial,” JAMA Oncology 6, no. 12 (2020): 1931–1938,

[27] Y. Ding, J. Jiang, J. Xu, et al., “Site-Specific Therapy in Cancers of Unknown Primary Site: A Systematic Review and Meta-Analysis,” ESMO Open 7, no. 2 (2022): 100407.

[28] E. Rassy, S. Boussios, and N. Pavlidis, “Genomic Correlates of Response and Resistance to Immune Checkpoint Inhibitors in Carcinomas of Unknown Primary,” European Journal of Clinical Investigation 51, no. 9 (2021): e13583.

[29] Z. Gatalica, J. Xiu, J. Swensen, and S. Vranic, “Comprehensive Analysis of Cancers of Unknown Primary for the Biomarkers of Response to Immune Checkpoint Blockade Therapy,” European Journal of Cancer (Oxford, England : 1990) 94 (2018): 179–186.

[30] L. M. Gay, D. Fabrizio, G. M. Frampton, et al., “ Mutational Burden of Tumors With Primary Site Unknown” supplement, 35, no. S15 (2017): 3039–3039,

[31] A. Krämer, F. Losa, L. M. Gay, et al., “ Genomic Profiling of Carcinomas of Unknown Primary (CUP) to Support Clinical Decisions” supplement, 36, no. S15 (2018): e24162.

[32] T. Bochtler, T. Wohlfromm, T. Hielscher, et al., “Prognostic Impact of Copy Number Alterations and Tumor Mutational Burden in Carcinoma of Unknown Primary,” Genes, Chromosomes & Cancer 61, no. 9 (2022): 551–560.

[33] P. A. Ott, Y. J. Bang, S. A Piha-Paul, et al., “T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated with Pembrolizumab Across 20 Cancers: KEYNOTE-028,” Journal of Clinical Oncology 37, no. 4 (2019): 318–327.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.